Literature DB >> 1728120

Helicobacter pylori and duodenal ulcer recurrence.

S Patchett1, S Beattie, E Leen, C Keane, C O'Morain.   

Abstract

Preliminary evidence suggests that eradication of Helicobacter pylori (H. pylori) may lead to prolonged remission of duodenal ulcer (DU). The aim of this study was to assess the long-term effect of eradication of H. pylori on the natural history of DU. Fifty-one patients with endoscopically proven duodenal ulcers, who were found to have H. pylori infection on histology and culture, and who were successfully eradicated of H. pylori with combination treatment of colloidal bismuth subcitrate and antibiotics, were studied. All patients were endoscoped at entry, 4 wk after cessation of treatment and again at 1 yr or sooner, if symptoms recurred. At each endoscopy, two antral biopsies were taken and assessed histologically and microbiologically for evidence of H. pylori infection. Recurrence of H. pylori infection occurred in 18/51 patients (35.3%) and, of these, 12 patients had evidence of recurrent peptic disease (five DU, seven duodenitis). In contrast, of the 33 who remained negative for H. pylori at 1 yr, none developed evidence of recurrent DU. Overall, DU recurrence occurred in 5/51 patients (11.7%), and occurred only in patients reinfected with H. pylori. This relapse rate compares favorably with patients on maintenance H2-receptor antagonist treatment. These results lend further support to the hypothesis that antral reinfection with H. pylori is associated with relapse of DU.

Entities:  

Mesh:

Year:  1992        PMID: 1728120

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  19 in total

Review 1.  Recurrence of Helicobacter pylori infection after successful eradication: nature and possible causes.

Authors:  H X Xia; N J Talley; C T Keane; C A O'Morain
Journal:  Dig Dis Sci       Date:  1997-09       Impact factor: 3.199

2.  Association between acute pancreatitis and peptic ulcer disease.

Authors:  Kang-Moon Lee; Chang-Nyol Paik; Woo Chul Chung; Jin Mo Yang
Journal:  World J Gastroenterol       Date:  2011-02-28       Impact factor: 5.742

3.  Protection against experimental Helicobacter pylori infection after immunization with inactivated H. pylori whole-cell vaccines.

Authors:  S Raghavan; M Hjulström; J Holmgren; A-M Svennerholm
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

Review 4.  A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.

Authors:  A Hackelsberger; P Malfertheiner
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

5.  Enhanced cultivation of Helicobacter pylori in liquid media.

Authors:  H X Xia; L English; C T Keane; C A O'Morain
Journal:  J Clin Pathol       Date:  1993-08       Impact factor: 3.411

6.  Identification of Helicobacter pylori DNA in the mouths and stomachs of patients with gastritis using PCR.

Authors:  N P Mapstone; D A Lynch; F A Lewis; A T Axon; D S Tompkins; M F Dixon; P Quirke
Journal:  J Clin Pathol       Date:  1993-06       Impact factor: 3.411

7.  Prevalence of metronidazole-resistant Helicobacter pylori in dyspeptic patients.

Authors:  H X Xia; M A Daw; S Beattie; C T Keane; C A O'Morain
Journal:  Ir J Med Sci       Date:  1993-03       Impact factor: 1.568

Review 8.  Indications for treatment of Helicobacter pylori infection: a systematic overview.

Authors:  S J Veldhuyzen van Zanten; P M Sherman
Journal:  CMAJ       Date:  1994-01-15       Impact factor: 8.262

Review 9.  Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: a systematic overview.

Authors:  S J Veldhuyzen van Zanten; P M Sherman
Journal:  CMAJ       Date:  1994-01-15       Impact factor: 8.262

10.  Effects of oral vaccination and immunomodulation by cholera toxin on experimental Helicobacter pylori infection, reinfection, and gastritis.

Authors:  S Raghavan; A-M Svennerholm; J Holmgren
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.